February 7, 2014
The Second Wave Arrives
Two more HCV drugs were newly approved in late 2013: the protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi).
By comparison to the two previously approved HCV protease inhibitors, simeprevir appears to be significantly more friendly toward coadministration with HIV medications (particularly HIV protease inhibitors) and has a high efficacy rate in HCV treatment-naive coinfected patients, even allowing many to dramatically shorten the typical course of HCV therapy. However, the drug must still be coadministered with peginterferon, leaving toxicity as a major issue.
Peginterferon is also part of a sofosbuvir-containing regimen at the moment, but only for genotype 1 patients. For patients with genotype 2 or 3, the drug is dosed alongside only ribavirin, and dramatically lower adverse event rates accompany that indication. Sofosbuvir also appears to have virtually no interactions with HIV antiretrovirals.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|HIV and Cardiovascular Disease|
|This Week in HIV Research: Helping HIV-Positive Smokers Quit; Alcohol and Sexual Decision-Making; Gender Differences; and More|
|Higher CD4 Counts -- But Not Statins -- Cut Risk of Heart Attack, Stroke and Mortality|
|ChemSex Versus Recreational Drug Use: A Proposed Definition for Health Workers|
|Diabetes Risk, Screening and Monitoring in People With HIV|
|High-Dose Vitamin D Supplementation Lowers HIV Replication In Vitro|